Jove
Visualize
Contact Us

Related Concept Videos

Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

4.0K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.0K
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

3.1K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.1K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

4.3K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: Methods for randomized, blinded, controlled evaluation of putative disease interventions in multilaboratory, preclinical assessment networks.

Lab animal·2026
Same author

Methods for randomized, blinded, controlled evaluation of putative disease interventions in multilaboratory, preclinical assessment networks.

Lab animal·2026
Same author

A Bayesian design for dual-agent dose optimization with targeted therapies.

Journal of biopharmaceutical statistics·2025
Same author

Clinician and Patient Perspectives on a Patient-Facing Online Breast Cancer Symptom Visualization Tool.

JCO clinical cancer informatics·2025
Same author

PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

Development of a Web-Based Interactive Tool for Visualizing Breast Cancer Clinical Trial Tolerability Data.

JCO clinical cancer informatics·2024
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 14, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K

Dose Finding in Oncology Trials Guided by Ordinal Toxicity Grades Using Continuous Dose Levels.

Mourad Tighiouart1, André Rogatko2

  • 1Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA 90069, USA.

Entropy (Basel, Switzerland)
|August 29, 2024
PubMed
Summary

This study introduces a novel Bayesian adaptive design for oncology dose-finding trials. The new method enhances patient safety by incorporating intermediate toxicity data, leading to more careful dose escalation and efficient maximum tolerated dose estimation.

Keywords:
cancer phase I trialscontinuous dosemaximum tolerated doseordinal toxicity gradeoverdose controlproportional odds model

More Related Videos

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.2K
Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

2.7K

Related Experiment Videos

Last Updated: Jun 14, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.2K
Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

2.7K

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Biostatistics

Background:

  • Traditional dose-finding trials often rely solely on binary dose-limiting toxicity (DLT) data.
  • This binary approach may not fully capture the spectrum of adverse events, potentially impacting patient safety during early-phase drug development.

Purpose of the Study:

  • To present a novel Bayesian adaptive design for dose-finding in early-phase oncology trials.
  • To enhance patient safety by incorporating intermediate toxicity grades (Grade 2) alongside DLTs.
  • To improve the efficiency of estimating the maximum tolerated dose (MTD).

Main Methods:

  • The design employs an escalation with overdose control principle.
  • It utilizes a proportional odds model to characterize the dose-toxicity relationship.
  • Intermediate Grade 2 toxicity data is integrated to guide dose adjustments, ensuring more cautious escalation.

Main Results:

  • The Bayesian adaptive design demonstrated safety and acceptable efficiency in estimating the MTD.
  • Operating characteristics were evaluated under various scenarios for true MTD and Grade 2 toxicity rates.
  • Simulations confirmed the design's robustness for a planned sample size of twenty patients.

Conclusions:

  • The proposed Bayesian adaptive design offers a safer and more refined approach to dose escalation in oncology.
  • Integrating intermediate toxicity data improves ethical considerations in first-in-human trials.
  • The design provides efficient MTD estimation, crucial for advancing novel cancer therapeutics.